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Abstract
Development of novel testing strategies to detect adverse human health effects is of interest to replace in vivo-based drug 
and chemical safety testing. The aim of the present study was to investigate whether physiologically based kinetic (PBK) 
modeling-facilitated conversion of in vitro toxicity data is an adequate approach to predict in vivo cardiotoxicity in humans. 
To enable evaluation of predictions made, methadone was selected as the model compound, being a compound for which 
data on both kinetics and cardiotoxicity in humans are available. A PBK model for methadone in humans was developed 
and evaluated against available kinetic data presenting an adequate match. Use of the developed PBK model to convert 
concentration–response curves for the effect of methadone on human-induced pluripotent stem cell-derived cardiomyocytes 
(hiPSC-CM) in the so-called multi electrode array (MEA) assay resulted in predictions for in vivo dose–response curves for 
methadone-induced cardiotoxicity that matched the available in vivo data. The results also revealed differences in protein 
plasma binding of methadone to be a potential factor underlying variation between individuals with respect to sensitivity 
towards the cardiotoxic effects of methadone. The present study provides a proof-of-principle of using PBK modeling-based 
reverse dosimetry of in vitro data for the prediction of cardiotoxicity in humans, providing a novel testing strategy in cardiac 
safety studies.
Keywords Cardiac electrophysiology · Methadone · Human induced pluripotent stem cell-derived cardiomyocytes 
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Abbreviations
ADME  Absorption, distribution, metabo-
lism and excretion
AIC  Akaike’s Information Criterion
AUC  Area under the curve
BMD  Benchmark dose
BMDL10—BMDU10  Lower and upper 95% confidence 
limit of BMD resulting in 10% 
effect
BMR  Benchmark response
BMC20  Benchmark concentration that 
induced a 20% change
EDDP  2-Ethylidene-1,5-dimethyl-3,3-di-
phenylpyrrolidine
EMDP  2-Ethyl-5-methyl-3,3-diphenylpyr-
roline
FPD  Field potential duration
FPDc  Field potential duration corrected 
for beat rate
hERG  Human ether-à-go-go-related gene
hiPSC-CM  Human induced pluripotent stem 
cell-derived cardiomyocytes
Cmax  Maximum concentration
MEA  Multi electrode array
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QIVIVE  Quantitative in vitro to in vivo 
extrapolation
Tdp  Torsade de pointes
fu,p  Unbound fraction in human plasma
fu,m  Unbound fraction in in vitro 
medium
Introduction
Traditional approaches for the risk and safety assessment 
of compounds rely heavily on toxicity data derived from 
laboratory animals, which are gradually being recognized 
as inappropriate models for the prediction of human health 
effects due to toxicodynamic and toxicokinetic differences 
between animals and human (Ewart et al. 2014; Pang et al. 
2019). This consideration as well as the fact that animal-
based testing strategies are cost and labor intensive, while 
also increasingly considered unethical, has stimulated the 
development of novel testing strategies, leading to a para-
digm shift in toxicity testing (Judson et al. 2014). Novel 
testing strategies generally apply in vitro assays and take into 
account insight in the modes of action underlying the toxic-
ity (Bernauer et al. 2005). However, in vitro assays provide 
hazard information and concentration–response curves that 
require translation to corresponding human dose–response 
curves, taking into account human toxicokinetics, to enable 
their use in human risk and safety assessment of compounds 
(Bell et al. 2018; Blaauboer 2010).
Over the last decade, several proof-of-principle studies 
indicated that combining in vitro toxicity assays with physio-
logically based kinetic (PBK) modeling, which describes the 
absorption, distribution, metabolism and excretion (ADME) 
of a compound in a defined species, can adequately predict 
in vivo dose–response curves (Louisse et al. 2017; Rietjens 
et al. 2011). For example, quantitative in vitro to in vivo 
extrapolation (QIVIVE) using PBK modeling-based reverse 
dosimetry was shown to adequately predict the in vivo tox-
icity for different endpoints, including developmental tox-
icity (Li et al. 2017; Louisse et al. 2010; Strikwold et al. 
2013, 2017), liver toxicity (Ning et al. 2017), nephrotox-
icity (Abdullah et al. 2016) and neurotoxicity (Zhao et al. 
2019). To further explore the potential applicability of this 
in vitro–in silico approach, the aim of the present study was 
to investigate whether the PBK modeling-based reverse 
dosimetry can be extended to predict in vivo cardiotoxic-
ity in human, thereby providing a novel testing strategy for 
cardiac safety testing.
Cardiotoxicity is an important endpoint in pharmaceutical 
safety testing and has been a leading cause of drug attrition 
in preclinical drug development (Pang et al. 2019; Stevens 
and Baker 2009). In addition, cardiotoxicity is also a rel-
evant endpoint in food safety, given that many food-borne 
alkaloids from botanicals and botanical preparations, includ-
ing, for example, synephrine from bitter orange (Citrus 
aurantium) and nuciferine from lotus (Nelumbo nucifera), 
raise a concern with respect to potential cardiotoxicity (Kratz 
et al. 2017). Potential cardiotoxicity includes functional and 
structural disruption of the cardiovascular system by inter-
fering with ion channels, intracellular organelles and cellular 
signaling pathways (Clements et al. 2015; Pang et al. 2019). 
Particularly, cardiac electrophysiological alterations such as 
delayed ventricular repolarization are endpoints of interest 
for cardiac safety assessment. Delayed ventricular repolari-
zation can result in a prolonged QTc interval (time from ven-
tricular depolarization and repolarization corrected for heart 
rate) in the electrocardiogram (ECG) which is associated 
with increased risk of arrhythmia including polymorphic 
ventricular tachyarrhythmia (torsade de pointes, Tdp) (Ewart 
et al. 2012; Harris et al. 2013; Kannankeril et al. 2010; Red-
fern et al. 2003; Wakefield et al. 2002). Current regulatory 
guidelines to evaluate in vitro electrophysiological cardio-
toxicity are based on ion channel inhibition assays using 
cell lines transfected with specific ion channels, including 
especially human ether-à-go-go-related gene (hERG) chan-
nels which play a critical role in cardiac repolarization (ICH 
2005a; Martin et al. 2004; Zwartsen et al. 2019). However, 
such an approach focussing on a single type of ion channel 
fails to address effects induced on other channels (Mirams 
et al. 2011; Rehnelt et al. 2017). Recently, human-induced 
pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) 
have been reported to provide a physiological relevant 
in  vitro model for human cardiotoxicity testing. These 
hiPSC-CM express major cardiac ion channels and show 
typical electrophysiological responses upon the exposure to 
compounds (Garg et al. 2018; Ma et al. 2011). In the pre-
sent study, hiPSC-CM were applied in combination with 
the multi electrode array (MEA) technique measuring the 
extracellular field potential of electrically active cardiomyo-
cytes, which is considered a promising tool to assess electro-
physiological alteration and arrhythmias (Ando et al. 2017; 
Harris et al. 2013; Kitaguchi et al. 2017; Li et al. 2016). The 
parameters obtained from extracellular field potential wave-
forms are considered to resemble the parameters observed 
in the human ECG (Zwartsen et al. 2019), which allows use 
of the hiPSC-CM MEA assay as an adequate in vitro model 
for QIVIVE.
The model compound selected for the present study was 
methadone (Fig. 1). Methadone is a synthetic drug for the 
treatment of opioid dependence and chronic pain. Metha-
done is metabolized by cytochromes P450 (CYP) mainly in 
the liver (Eap et al. 2002; Nilsson et al. 1982). The primary 
metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrroli-
dine (EDDP), is formed via N-demethylation and cyclisa-
tion, and a subsequent N-demethylation leads to the sec-
ondary metabolite, 2-ethyl-5-methyl-3,3-diphenylpyrroline 
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(EMDP) (Fig. 1). Methadone has been reported to cause 
cardiotoxic side effects in human clinical studies in which 
prolonged QTc interval and TdP have been observed in sub-
jects receiving methadone maintenance treatment (Aline-
jad et al. 2015; Eap et al. 2002; Justo et al. 2006). Several 
in vitro studies using electrophysiological-based patch clamp 
demonstrated an association between the cardiotoxicity of 
methadone and the inhibition of hERG channels (Eap et al. 
2007; Kuryshev et al. 2010).
In the present study, the in vitro concentration-dependent 
cardiotoxicity of methadone and its metabolites EDDP and 
EMDP was quantified in hiPSC-CM using the MEA tech-
nique. Additionally, a PBK model for methadone kinetics in 
human was developed by integrating data from literature as 
well as experimentally obtained metabolic parameters. This 
PBK model was subsequently used to translate the in vitro 
toxicity data to predict in vivo cardiotoxicity in human. The 
data thus obtained were compared to available data on the 
effect of methadone on cardiac parameters in subjects that 
received methadone maintenance treatment.
Materials and methods
Chemical and biological materials
Methadone hydrochloride (≥ 98%), EDDP perchlorate 
(≥ 98%), EMDP hydrochloride solution (1.0 mg/ml), Tris 
(hydroxymethyl) aminomethane  (Trizma® base), ammonium 
formate and fibronectin were purchased from Sigma-Aldrich 
(Zwijndrecht, The Netherlands). Methadone and metabolites 
were ordered under the opium exemption license number 
104783 03 WCO, which is registered at Farmatec (executive 
organization of the Ministry of Health, Welfare and Sport, 
The Hague, The Netherlands). Dimethyl sulfoxide (DMSO, 
99.7%) was obtained from Merck (Schiphol-Rijk, The 
Netherlands). Phosphate-buffered saline (PBS) was pur-
chased from Gibco (Paisley, Scotland, UK). Acetonitrile 
(UPLC/MS grade) was obtained from Biosolve BV (Valk-
enswaard, The Netherlands). hiPSC-CM  (Pluricyte® Cardio-
myocytes, cat# PCMI-1031-1, lot# 60151) and  Pluricyte® 
Cardiomyocyte medium were obtained from Ncardia (Lei-
den, The Netherlands). Pooled human liver microsomes 
(from 150 donors), pooled human intestinal microsomes 
(from 7 donors) and reduced nicotinamide adenine dinu-
cleotide phosphate (NADPH) regenerating system solution 
A and solution B were purchased from Corning (Woburn, 
MA, USA). Pooled human plasma and rapid equilibrium 
dialysis (RED) materials, including RED inserts, RED base 
plates and sealing tape were obtained from Thermo Fisher 
Scientific (Bleiswijk, The Netherlands).
General outline of the PBK modeling‑based reverse 
dosimetry approach
The PBK modeling-based reverse dosimetry approach 
to predict the in vivo dose–response curves from in vitro 
cardiotoxicity concentration–response data included the 
following steps: (1) establishment of the in vitro concen-
tration–response curves for methadone and its metabo-
lites EDDP and EMDP in hiPSC-CM using the MEA, 
(2) development of a PBK model for methadone and its 
metabolites in human using metabolic parameters obtained 
from in vitro incubations with pooled human liver micro-
somes, and parameters derived from in silico simulations 
and the literature, (3) evaluation of the PBK model, (4) 
translation of in vitro concentration–response curves to 
in vivo dose–response curves using the PBK model, and (5) 
evaluation of the PBK modeling-based reverse dosimetry 
approach by comparing predicted dose–response data to 
data obtained from literature on the effect of methadone on 
cardiac parameters in subjects receiving methadone main-
tenance treatment.
In vitro cardiotoxicity of methadone 
and metabolites in hiPSC‑CM using the MEA
The MEA system of Multi Channel System (MCS GmbH, 
Ruetlingen, Germany) combined with  Pluricyte® Cardio-
myocytes was used to detect the cardiotoxicity of metha-
done, and the metabolites EDDP and EMDP. The  Pluricyte® 
Cardiomyocytes were thawed and seeded on the six-well 
MEA chips (60-6well MEA200/30iR-Ti-tcr, MCS GmbH) 
according to the manufacturer’s protocol. Briefly, each well 
of the MEA chips was precoated with 50 μg/ml fibronectin 
for 3 h in the incubator at 37 °C with 5%  CO2. The fibronec-
tin coating solution was aspirated before seeding. Cells 
were thawed in the incubator at 37 °C for exactly 4 min and 
Fig. 1  Metabolic conversion 
of methadone to 2-ethylidene-
1,5-dimethyl-3,3-diphenylpyr-
rolidine (EDDP), and 2-ethyl-
5-methyl-3,3-diphenylpyrroline 
(EMDP) by cytochrome P450 
(CYP450)
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carefully transferred to a 50-ml tube. The original vial was 
rinsed with serum free  Pluricyte® Cardiomyocyte Medium 
and added drop-wise to the tube containing the cardiomyo-
cytes. Subsequently, cell counting was manually performed, 
using 20 μl of obtained homogenous cell suspension in a 
Buerker-Tuerk Counting Chamber (Marienfeld Superior 
GmbH & Co. KG, Lauda-Königshofen, Germany) and at 
the same time the remaining cells were centrifuged at 300g 
for 3 min. Then, the supernatant was removed and medium 
was drop-wisely added to reach the aimed concentration of 
cells in the suspension  (104 cells/μl). 2-μl cell suspension 
per well was placed on the six-well MEA chips in a den-
sity of  104 cells/μl. After 3-h incubation (37 °C, 5%  CO2), 
200 μl of medium was filled into each well of the MEA chips 
which were subsequently incubated at 37 °C with 5%  CO2 
and refreshed with medium every 2 days.
At 7–8 days after seeding, MEA chips were placed on the 
headstage of a MEA2100-system (MCS GmbH) integrated 
with the chamber providing a stable atmosphere (37 °C, 5% 
 CO2) to record the extracellular field potential (Fig. 2) of 
spontaneous beating hiPSC-CM. After an equilibration time 
of 20 min, half of the medium (100 μl) in each well was 
replaced by culture medium containing 0.2% (v/v) DMSO 
to reach a final concentration of 0.1% (v/v) DMSO, which 
was used as baseline condition. Subsequently, the model 
compounds were tested in separate wells, and each test com-
pound was cumulatively added to the well with increasing 
concentrations in the same way (Harris et al. 2013; Nozaki 
et al. 2017; Ando et al. 2017). At each concentration, the 
extracellular field potential was recorded for 1 min after 
10-min exposure. Stock solutions of model compounds 
were prepared in DMSO and further diluted in  Pluricyte® 
Cardiomyocyte medium to make exposure medium with the 
final concentration of 0.1% (v/v) DMSO. The following con-
centrations were tested, 0.01, 0.03, 0.1, 0.2, 0.3, 0.4, 1, 3, 
10, 30 µM (methadone), 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30 µM 
(EDDP) and 0.1, 0.3, 1, 3, 10, 30 µM (EMDP), at which no 
cytotoxicity was observed (data not shown). The test con-
centrations of methadone were based on reported human 
methadone plasma concentrations that were observed after 
oral methadone treatment. Same test concentrations were 
chosen for EDDP and EMDP, which enables definition of 
concentration-dependent curves for EDDP and EMDP that 
allow potency comparison.
One well of 0.1% (v/v) DMSO on each MEA chip was 
used as the vehicle control well and run at the same time 
as the compound exposure wells to correct for time- and 
DMSO-dependent effects on the field potential. A detailed 
exposure scheme can be found in Fig. S1. Data were col-
lected using Cardio 2D software (MCS GmbH) with a sam-
ple frequency of 10 kHz and a 0.1–3.5-kHz band-pass filter.
After exposure, MEA data generated from the electrodes 
showing stable baseline field potential with clearly visible 
depolarization (peak amplitude ≥ 200 μV) and repolarization 
peaks (peak amplitude ≥ 20 μV) (Ando et al. 2017; Sala et al. 
2017) were selected for further analysis using Multiwell-
Analyzer software Version 1.5.1.0 (MCS GmbH). Field 
potential duration (FPD) was defined as duration between 
the beginning of the sodium spike and the repolarizing peak 
(Fig. 2). RR-intervals were defined as the duration between 
two depolarization peaks (Fig. 2). The FPD and RR-interval 
were measured as the average of at least 30 beats from 1-min 
recording at each concentration of the test compound. In 
addition, the Fridericia formula (Eq. 1) was applied to cor-
rect for the effect of beat rate on FPD (Vandenberk et al. 
2016) as widely used in other MEA studies (Ando et al. 
2017; Kitaguchi et al. 2017):
In this formula, the FPD and RR-interval are expressed in 
seconds. Data were collected from at least three independ-
ent experiments (4–8 wells, 26–38 electrodes), using a new 
(1)FPDc =
FPD
3
√
RR interval
.
Fig. 2  Typical extracellular field potential waveform consisting of a 
rapid upstroke corresponding to depolarization, a slow wave/plateau 
and a repolarization peak. Signals were generated under the baseline 
condition (0.1% (v/v) DMSO) in Pluricyte cardiomyocytes cultured 
in six-well MEA-chips measured by the MEA2100-System platform 
of MCS
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vial of cells (all from the same batch) at each independ-
ent experiment. In vitro cardiotoxic effects are expressed as 
relative percentage of FPDc compared to the FPDc results 
obtained for the baseline condition [0.1% (v/v) DMSO] and 
further corrected for the time- and DMSO-dependent effects 
by subtracting the response of 0.1% (v/v) DMSO obtained 
from the corresponding time-matched vehicle control well. 
The concentrations inducing irregularities in the field 
potential trace (Fig. S2) were also noted. Such irregularities 
included arrhythmia-type changes in the waveform, a flat-
tened unclear second peak and/or beating arrest (Asakura 
et al. 2015; Kitaguchi et al. 2017; Nakamura et al. 2014; 
Zwartsen et al. 2019). Concentrations inducing these irregu-
larities were excluded from the FPD analysis since the FPD 
and RR-interval could not be determined.
Effective concentrations expressed as the FPDc (% to the 
baseline control) were determined using the benchmark dose 
(BMD) approach which was performed as described in the 
“Evaluation of the PBK modeling-based reverse dosimetry 
approach”. The concentration–response curves were plotted 
with GraphPad Prism 5.0 using the four-parameters logistic 
fit (GraphPad Software Inc., San Diego, USA). Each data 
point is presented as the mean value of at least three inde-
pendent experiments ± standard deviation (SD). Statistical 
significance of the changes in response of cells exposed to 
the compound compared to the solvent control was ana-
lyzed by one-way ANOVA followed by post Dunnett test. 
Values of p < 0.05 were regarded as statistically significant 
(p < 0.05: *, p < 0.01: ** and p < 0.001: ***). Statistical 
analysis was performed by GraphPad Prism 5.0 (GraphPad 
Software Inc.).
In vitro microsomal incubations
In vitro incubations were performed to obtain the kinetic 
parameters for the conversion of methadone by human liver 
microsomes. To this end, incubation conditions were opti-
mized to obtain linear reaction rates with respect to microso-
mal protein levels (0.1–2 mg/ml protein) and incubation time 
(1–120 min) at 50-µM methadone. The final incubation mix-
tures (final volume of 160 µl) consisted of 0.1-M Tris–HCl 
(pH 7.4–7.5), NADPH regeneration system (final concen-
trations 1.3-mM  NADP+, 3.3-mM glucose-6-phosphate, 
0.4-U/ml glucose-6-phosphate dehydrogenase and 3.3-mM 
magnesium chloride) and methadone at eight final concen-
trations ranging from 10 to 1500 µM diluted from a 100-mM 
stock solution in water. The test concentrations were chosen 
to enable adequate analysis of Michaelis–Menten kinetics. 
After one-min pre-incubation of this solution at 37 °C, the 
reactions were initiated by addition of human liver micro-
somes giving a final concentration of 0.5 mg/ml microso-
mal protein and incubations were performed in a shaking 
water bath at 37 °C for 40 min. Control incubations were 
performed in the absence of NADPH which was replaced 
with Tris–HCl. The reactions were terminated by addition 
of 40-µl ice-cold acetonitrile. Samples were kept on ice for 
at least 20 min and then centrifuged at 18,000g for 5 min 
at 4 °C to precipitate microsomal proteins. The superna-
tant was collected for the quantification of EDDP forma-
tion, which was analyzed by Ultra-Performance Liquid 
Chromatography PhotoDiode Array (UPLC-PDA, Waters) 
as described in the “Quantification of methadone and its 
metabolites by UPLC–PDA analysis” section.
The formation of the secondary metabolite EMDP from 
EDDP was investigated by incubating 1000-µM EDDP 
under the same conditions as described above for the micro-
somal methadone incubations. The kinetic parameters for 
the conversion of methadone by intestinal microsomes 
were determined under the same conditions as the incuba-
tions with liver microsomes after the incubation conditions 
were optimized with respect to microsomal protein levels 
(0.1–2 mg/ml protein) and incubation time (1–120 min) at 
50-µM methadone.
The apparent maximum velocity (Vmax) and the apparent 
Michaelis–Menten constant (Km) describing the conversion 
of methadone to EDDP were determined using the Michae-
lis–Menten Eq. (2):
where [S] is the substrate concentration (µM) and v is the 
rate of EDDP formation (nmol/min/mg protein). Vmax and 
Km were obtained by fitting the data to Eq. (2) in GraphPad 
Prism 5.0 (GraphPad Software Inc.). Data were collected 
from three independent experiments and each data point is 
presented as the mean value ± SD.
Determination of unbound fraction of methadone 
and EDDP in in vitro hiPSC‑CM MEA assay medium 
and in human plasma
The rapid equilibrium dialysis (RED) assay was performed 
to determine the unbound fraction (fu) of methadone and 
EDDP in in vitro medium and in pooled human plasma using 
the protocol adapted from the manufacturer of the RED 
device (Thermo Fisher Scientific 2017). In short, metha-
done or EDDP was added to the in vitro medium or pooled 
human plasma to reach a concentration of 150 µM in test 
sample solution and PBS was used as buffer. 300-µl test 
sample solution and 500-µl PBS were, respectively, added 
to the sample chamber and the buffer chamber of the RED 
insert, which was subsequently incubated for 5 h at 37 °C 
at 250 rpm on an orbital shaker to reach equilibrium (van 
Liempd et al. 2011). Then, 25 µl of post-dialysis samples 
were collected from the sample chambers and transferred 
(2)v =
Vmax × [S]
Km + [S]
,
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to test sample tubes followed by an addition of 25 µl PBS. 
Equal volumes of post-dialysis samples collected from the 
buffer chamber which were then mixed with 25 µl of in vitro 
medium or human plasma in the buffer sample tubes. Then, 
both samples were precipitated using 300-µl cold acetoni-
trile/water (90/10 v/v). The samples were put on ice for 
30 min followed by centrifugation for 30 min at 15,000g. 
Then, supernatants were collected for UPLC–PDA analy-
sis. The fraction unbound was calculated with Eq. (3) (van 
Liempd et al. 2011; Waters et al. 2008):
The measurements were performed in triplicate in two 
independent experiments.
Quantification of methadone and its metabolites 
by UPLC–PDA analysis
The quantification of methadone and its metabolites 
was performed by UPLC–PDA analysis using a Waters 
Acquity UPLC H_class system (Etten-Leur, The Nether-
lands) equipped with a Waters Acquity BEH C18 (1.7 µm, 
2.1 × 50 mm) column. For optimal separation, a gradient 
of 20-mM ammonium formate (pH = 5.7) (solvent A) and 
acetonitrile (solvent B) with a flow rate of 0.3 ml/min was 
applied as follows: the initial condition was 90:10 (A:B); 
then the gradient was increased linear to 98% B over 8 min; 
then set to the initial conditions in 2 min and re-equilibrated 
for 5 min. Retention times of methadone, EDDP and EMDP 
were 4.7, 4.4 and 6.3 min, respectively. Identification of 
(3)fu =
concentration in buffer chamer
concentration in sample chamer
methadone and its metabolites was based on comparison 
of their retention time and UV spectrum to those of com-
mercially available reference compounds. Quantification was 
based on comparison of the respective peak areas to the peak 
areas of corresponding calibration curves which were pre-
pared using the reference compounds (R2 > 0.999).
Establishment of the PBK model for methadone 
and EDDP
In the present paper, a PBK model describing the ADME of 
methadone and its major metabolites in human was devel-
oped. Figure 3 presents the schematic diagram of the PBK 
model including a submodel for the major metabolite EDDP 
and the compartments relevant for the ADME characteris-
tics of methadone and EDDP. A submodel for EDDP was 
included to enable the prediction of internal concentrations 
of EDDP required to evaluate if EDDP will be formed in 
quantities that are relevant for cardiotoxicity. Consider-
ing that methadone is usually administered to the opioid 
dependent population or patients with chronic pain on a 
daily basis, a PBK model for repeated dosing of methadone 
was developed.
The absorption rate constant (ka) and fraction absorbed 
(Fa) are two key parameters describing the absorption of 
methadone. The uptake of methadone from the gastrointes-
tinal (GI) tract was reported to follow a first-order process 
(Yang et al. 2006) with a mean ka value of 0.59/h obtained 
from several studies (Foster et al. 2000; Wolff et al. 2000). 
A mean Fa value of 0.88 was reported by Ke et al. (2014).
To describe the distribution, tissue: blood partition coef-
ficients (P) of methadone and EDDP were obtained by 
Fig. 3  Schematic diagram of the PBK model of methadone including a submodel for EDDP
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dividing tissue: plasma partition coefficients by the corre-
sponding blood/plasma ratio (BPr) obtained from subjects 
on methadone maintenance treatment (Hsu et al. 2013), to 
correct for the differences in the distribution of the com-
pounds in blood and plasma. The tissue: plasma parti-
tion coefficients of methadone and EDDP were calculated 
using prediction method 1 which applies the algorithms of 
Berezhkovskiy (2004) in the Simcyp Simulator V18 Release 
1 (Certara, Sheffield, UK) requiring information on the 
fraction unbound in plasma (fu,p), lipophilicity (logP) and 
acid–base properties (pKa). The logP and pKa values of 
methadone were obtained from literature (Gerber et al. 2001; 
Ke et al. 2014). The logP and pKa of EDDP were obtained 
from Marvinsketch (ChemAxon, Hungary). The fu,p of meth-
adone was obtained from the in silico Simcyp prediction tool 
(Certara). The fu,p value of 0.3 for EDDP was obtained from 
the study of Moody et al. (2008). The fu,p of methadone and 
EDDP were also measured using pooled human plasma in 
the current study (see “RED assay” section). Since the influ-
ence of blood: tissue partition coefficients derived based on 
different fu,p values on the model output was negligible (data 
not shown), the blood: tissue partition coefficients calculated 
with the Simcyp-derived fu,p were used.
Liver was identified as the metabolizing organ in the PBK 
model since conversion of methadone was reported to pri-
marily occur in the liver (Foster et al. 2004; Totah et al. 
2008). Although Oda and Kharasch (2001) observed conver-
sion of methadone in in vitro human intestinal microsomal 
incubations, the contribution of this intestinal metabolism to 
the elimination of methadone in vivo seems to be relatively 
small compared to the contribution of hepatic metabolism 
(Ke et al. 2014). Given that only minor methadone deple-
tion was observed in the incubations with pooled intestinal 
microsomes (see “In vitro microsomal incubations”), intesti-
nal metabolism was not considered in the model. Conversion 
of EDDP into EMDP was not included in the model since no 
EMDP measured in the microsomal incubations with EDDP 
(see “In vitro microsomal incubations”). The in vitro Vmax 
obtained from human liver microsomal incubations were 
scaled to the in vivo situation taking the total liver microso-
mal protein yield of 32 mg microsomal protein/g liver into 
account (Barter et al. 2007).
After oral dosing, the urinary excretion of methadone and 
its metabolites accounts for up to 50% of the given dose 
(Ånggård et al. 1975; Lugo et al. 2005; Sullivan and Due 
1973) with the ratio of unchanged methadone to EDDP rang-
ing between 1/1 and 1/5 (Kharasch et al. 2004, 2009; Ver-
ebely et al. 1975). Therefore, urinary excretion of methadone 
and EDDP was included in the PBK model. In addition, 
biliary excretion was included in the submodel of EDDP 
since the recovery of EDDP in feces was reported to account 
for up to 39% (Foster 2001). The renal clearance of metha-
done (RCLmet) was set at 1.45 l/h which was the average 
of the values reported in different in vivo studies (Boulton 
et al. 2001; Foster et al. 2000; Kharasch et al. 2009). The 
renal clearance (RCLeddp) and biliary excretion rate con-
stant (kbile) of EDDP were obtained by the curve fitting 
option in Berkeley Madonna (version 8.3.18, UC Berkeley, 
CA, USA) in which the steady-state blood maximum con-
centration (Cmax) of EDDP obtained with the PBK model 
was fitted to the steady-state blood Cmax of EDDP that was 
reported in subjects receiving methadone maintenance treat-
ment with an oral dose of 57.5 mg/day (De Vos et al. 1995). 
This resulted in the fitted rate constants for RCLeddp and 
Kbile of 19.99 l/h and 1.65/h (Table 1), respectively. Kinetic 
model calculations and curve fitting were performed with 
Berkeley Madonna, applying Rosenbrock’s algorithms for 
solving stiff systems. Model equations are shown in supple-
mentary materials 2. Human physiological parameters used 
in the PBK model were obtained from Brown et al. (1997) 
(Table 1). Table 2 shows the physicochemical parameters of 
methadone and EDDP.
Evaluation of the PBK model
To evaluate the performance of the PBK model developed, 
comparisons were made between predicted blood concentra-
tions and area under the curve (AUC) values of methadone 
and in vivo blood concentrations and AUC values obtained 
in clinical studies with repeated daily oral administration 
at different doses of methadone. Given that the kinetics of 
methadone were reported based on plasma concentrations in 
clinical studies, the plasma concentration–time curves were 
extracted from graphs presented in the respective clinical 
studies using GetData Graph Digitizer 2.261 and further con-
verted to blood concentration–time curves by multiplying 
with the BPr value. For the evaluation of the PBK model, 
the model parameter body weight and the oral dose were 
chosen to match the values used in the clinical studies. The 
specifications of in vivo kinetic studies of methadone used to 
evaluate the PBK model are summarized in Table 4.
Sensitivity analysis
A local parameter sensitivity analysis was performed to 
identify influential parameters on the predicted Cmax in the 
heart venous blood during the steady-state phase. The nor-
malized sensitivity coefficient (SC) was calculated with the 
following Eq. (4):
1 Available at: https ://getda ta-graph -digit izer.com [Accessed 20th 
November 2019].
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where C is the initial value of the model output being the 
steady-state Cmax of the heart venous blood, C′ is the model 
(4)SC =
(
C� − C
)
(P� − P)
×
P
C
output after a 1% increase in each model parameter value, P 
is the initial parameter value and P′ is the parameter value 
after a 1% increase. Parameters with an absolute SC > 0.1 
are considered to be influential on the model output (Chiu 
et al. 2007; Rietjens et al. 2011). The sensitivity analysis was 
carried out for a subject with a body weight of 70 kg (Brown 
et al. 1997) and for oral daily doses of 20 and 200 mg, rep-
resenting, respectively, a clinically relevant dose level and a 
Table 1  Physiological and 
biochemical parameters used in 
the PBK model for methadone 
and EDDP
a Fitted value generated from EDDP data presented in the study of De Vos et al. (1995)
Parameters Symbol Value References
Body weight (kg) BW 70 Brown et al. (1997)
Tissue volume (% body weight) Brown et al. (1997)
 Liver VLc 0.0257
 Fat VFc 0.2142
 Lung VLuc 0.0076
 Arterial blood VAc 0.0198
 Venous blood VVc 0.0593
 Kidney VKc 0.004
 Heart VHc 0.0047
 Slowly perfused tissue VSc 0.5318
 Rapidly perfused tissue VRc 0.052
 Cardiac output (l/h) Qc 347.9
Blood flow to tissue (% cardiac output) Brown et al. (1997)
 Liver QLc 0.227
 Fat QFc 0.052
 Kidney QKc 0.175
 Heart QHc 0.04
 Slowly perfused tissue QSc 0.188
 Rapidly perfused tissue QRc 0.318
Absorption rate constant of methadone (/h) ka 0.59 Foster et al. (2000); Wolff et al. (2000)
Fraction absorbed of methadone Fa 0.88 Ke et al. (2014)
Renal clearance of methadone (l/h) RCLmet 1.45 Boulton et al. (2001); Foster et al. 
(2000); Kharasch et al. (2009)
Renal clearance of EDDP (l/h) RCLeddp 19.99a Fitted values
Biliary excretion rate constant of EDDP (/h) kbile 1.65a Fitted values
Table 2  Physicochemical 
parameters for methadone and 
EDDP
BPr blood/plasma ratio
a Reported in Ke et al. (2014)
b Reported in Gerber et al. (2001)
c Reported in Hsu et al. (2013)
d Obtained by dividing tissue: plasma partition coefficients by the corresponding BPr values
e Obtained from Marvinsketch (ChemAxon)
Compound LogP pKa BPr Tissue: blood partition  coefficientsd
Liver Fat Slowly 
perfused 
tissue
Rapidly 
perfused 
tissue
Lung Kidney Heart
Methadone 3.93a 9.20b 0.70c 12.45 0.46 7.67 12.45 1.77 7.56 4.9
EDDP 4.63e 9.64e 0.87c 11.51 0.18 7.06 11.51 1.56 6.95 4.48
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dose level associated with a high proportion of case reports 
of cardiotoxicity in subjects receiving methadone (Chou 
et al. 2014).
Translation of in vitro concentration–response 
data to in vivo dose–response data using PBK 
modeling‑based reverse dosimetry
A change in the FPDc in the vitro field potential waveforms 
can be considered the surrogate endpoint for the QTc inter-
val in the human ECG (Zwartsen et al. 2019). Based on 
this consideration, PBK modeling-based reverse dosimetry 
was applied to translate in vitro concentration–response 
data on FPDc obtained from the hiPSC-CM using the MEA 
to in vivo dose–response curves for QTc. To this purpose, 
the in vitro unbound concentrations of methadone tested in 
the hiPSC-CM MEA assay were set equal to the unbound 
steady-state Cmax of methadone in the heart venous blood 
by correcting the fraction unbound in plasma to a fraction 
unbound in blood using the BPr value in Eq. (5):
where Ctotal,invitro and fu,m are the in vitro methadone concen-
tration and unbound fraction of methadone in the in vitro 
exposure medium, respectively. BPr is the blood to plasma 
ratio of methadone and fu,p is the unbound fraction of metha-
done in human plasma. Ctotal,humanblood values were extrapo-
lated to in vivo oral doses by PBK modeling-based reverse 
dosimetry, using a bodyweight of 70 kg (Brown et al. 1997). 
The same procedure was performed for each of the in vitro 
concentrations tested in the MEA. Thus, the entire in vitro 
concentration–response curve was translated to a predicted 
in vivo dose–response curve.
Evaluation of the PBK modeling‑based reverse 
dosimetry approach
To evaluate the performance of the PBK modeling-based 
reverse dosimetry approach, the predicted dose–response 
curves were compared to dose–response data for QTc 
prolongation obtained from published literature including 
single case reports, case series (Table S1), cross-sectional, 
retrospective and prospective studies (Table S2). To better 
illustrate the dose-dependent effect of methadone on QTc 
prolongation, individuals who have potential QTc prolong-
ing risk factors including structural heart disease, electrolyte 
imbalance, hepatic impairment, concomitant use of medica-
tions that potentially prolong QTc or influence the metab-
olism of methadone (Stringer et al. 2009) were excluded 
from case reports and case series used for the evaluation. 
Similar criteria could not be applied to the cross-sectional, 
(5)Ctotal, in vitro ⋅ fu, m = Ctotal, human blood ⋅
fu, p
BPr
retrospective and prospective studies due to the absence of 
detailed individual information on these risk factors. Poten-
tial QTc prolonging risk factors and exclusion criteria for 
these studies are summarized in Table S2. To facilitate the 
comparison between in vitro- and in vivo-derived values, 
both the absolute FPDc values obtained from the in vitro 
cardiotoxicity assay and the in vivo methadone-induced QTc 
prolongation on ECG were expressed as relative percentages 
by dividing the post-treatment FPDc and QTc values by the 
respective baseline values. For the studies in which baseline 
QTc data were not reported, a population baseline QTc was 
assumed as described in the study of Florian et al. (2012) 
in which baseline QTc was set equal to baseline QTc values 
identified in Wedam et al. (2007), with an average value of 
407 ms (411 ms for female; 405 ms for male).
Benchmark dose modeling
BMD analysis of predicted in vivo dose–response curves 
was performed to derive a BMD that can be used as point 
of comparison to evaluate the predicted dose–response data 
against therapeutic methadone levels reported in the litera-
ture. The benchmark response (BMR) was defined as a 10% 
change compared to the control. For the QTc, an effect of 
10% change over the population baseline of 407 ms, amount-
ing to a QTc of 450 ms is frequently used as a threshold 
for abnormal QTc prolongation (Anchersen et al. 2009; 
Chou et al. 2014; ICH 2005b; Mujtaba et al. 2013; Treece 
et al. 2018). The BMD values resulting in a BMR of 10% 
with lower and upper 95% confidence limit were defined 
as  BMDL10 and  BMDU10. The European Food Safety 
Authority (EFSA) web-tool2 integrated with the R-package 
PROAST version 66.40 developed by the Dutch National 
Institute for Public Health and the Environment (RIVM) was 
used for BMD analysis. In short, the continuous data from 
the predicted in vivo dose–response curves were fitted to a 
set of models including the Exponential, Hill, Inverse Expo-
nential, and the Log-Normal Family models. According to 
the flow-chart described in the  manual2 provided by EFSA, 
all fitted models excluding the FULL and NULL model were 
used for model averaging and a weighted average model was 
constructed to estimate model averaged confidence inter-
vals using bootstrap sampling (Wheeler and Bailer 2007). 
Weighting was based on the model’s Akaike’s Information 
Criterion (AIC) values where models with lower AIC val-
ues get a larger weight. 200 bootstrap data sets were run to 
calculate the final BMD confidence intervals from model 
averaging.
2 EFSA Statistical Models-BMD. [Online]. Available at: https ://shiny 
-efsa.opena nalyt ics.eu/app/bmd [Accessed 20 December, 2019]
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In vitro concentration–response cardiotoxicity data 
were analyzed using the same BMD approach to derive 
benchmark concentrations that induced a 20% change 
in the FPDc over the control  (BMC20) for comparing 
the potency of methadone, EDDP and EMDP. The final 
 BMC20 values were obtained by weighted averaging 
 BMC20 values derived from all fitted models excluding 
the FULL and NULL model. For this analysis, a BMR of 
20% was chosen being the lowest BMR allowing reliable 
curve fitting.
Results
In vitro cardiotoxicity in the hiPSC‑CM MEA assay
Figure 4 shows the cardiotoxicity of methadone, EDDP 
and EMDP in hiPSC-CM as detected in the MEA. Metha-
done and its primary metabolite EDDP significantly pro-
longed the FPDc in a concentration-dependent manner 
with a  BMC20 of 0.6 µM and 2.3 µM, respectively. Of 
interest to note is that the secondary metabolite EMDP 
induced an opposite effect, shortening the FPDc in a 
concentration-dependent manner with the concentration 
shortening the FPDc by 20% amounting to 3.8 µM. Both 
methadone and EDDP induced arrhythmia-like wave-
forms from 3 µM onwards; while, cessation of beating was 
observed upon the treatment of the hiPSC-CM with metha-
done and EDDP at 30 µM. EMDP caused beating arrest in 
certain wells at 30 µM without inducing arrhythmia-type 
waveforms within the test concentration range. The FPDc 
of hiPSC-CM treated with repeated application of 0.1% 
(v/v) DMSO in the vehicle control well was not signifi-
cantly affected (Fig. S3).
In vitro microsomal incubations
Figure 5 shows the concentration-dependent formation rate 
of EDDP from methadone by human liver microsomes, 
which followed Michaelis–Menten kinetics. The apparent 
Vmax and Km values obtained from the data, and the catalytic 
efficiency (Vmax/Km) are presented in Table 3. No EMDP for-
mation was measured in these incubations. In similar incu-
bations using EDDP as the substrate, formation of EMDP 
was neither detectable. In incubations with intestinal micro-
somes applying the two highest methadone concentrations 
tested in liver microsomes (1000 and 1500 µM), formation 
of EDDP was less than 8% of the formation observed with 
liver microsomes at these concentrations. In addition, neg-
ligible formation of EDDP was observed in the incubation 
of 50-µM methadone with increasing incubation time up to 
120 min and protein concentrations up to 2-mg/ml human 
intestinal microsomal protein. Also in these incubations, no 
EMDP formation was detected. This implied that conversion 
by intestinal microsomes was considered limited compared 
to conversion by human liver microsomes and therefore 
methadone conversion by intestinal tissue was not incor-
porated in the PBK model and, hence, no further kinetic 
constants were derived. Fig. 4  Concentration–response curves for the effect of methadone (circles), EDDP (squares) and EMDP (triangles) on FPDc in hiPSC-
CM detected by the MEA. The response of the baseline condition 
(0.1% (v/v) DMSO) was set at 100%. Data represent the mean of 4–9 
wells with in total 26–38 electrodes. Each data point represents the 
mean ± SD. Statistically significant changes in response compared to 
the solvent control are marked with * with p < 0.05: *, p < 0.01: ** 
and p < 0.001: ***
Fig. 5  Concentration-dependent formation of EDDP in incubations 
with human liver microsomes. Data represent the mean of three inde-
pendent experiments. Each data point represents the mean ± SD
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Unbound fraction for methadone in in vitro 
hiPSC‑CM MEA medium and in human plasma
Due to the use of serum-free medium in the hiPSC-
CM MEA assay, the unbound fraction of methadone in 
the in  vitro medium was relatively high, amounting to 
0.79 ± 0.041 compared to the unbound fraction in pooled 
human plasma determined to be 0.055 ± 0.011. The unbound 
fraction of EDDP in the in vitro medium was 0.90 ± 0.072 
and was 0.30 ± 0.015 in pooled human plasma.
Considering the large inter-individual variation in plasma 
protein binding for methadone observed in in vivo studies 
(Eap et al. 1990; Olsen 1973; Romach et al. 1981; Wilkins 
et al. 1997), also two extreme fu,p values (0.034 and 0.22) 
obtained from the literature together with the Simcyp-
derived and RED-derived fu,p values (0.15 and 0.055, respec-
tively) were used to translate in vitro effect concentrations to 
the total blood concentration as presented in Eq. (5), which 
were subsequently subject to PBK modeling-based reverse 
dosimetry.
PBK model development and evaluation
To evaluate the performance of the human PBK model, 
the predicted methadone blood kinetics were compared 
to in vivo human data obtained from the literature. The 
specifications of in vivo studies on the subjects receiving 
methadone maintenance treatment that are used for the PBK 
model evaluation are summarized in Table 4. As illustrated 
in Fig. 6, the developed PBK model accurately predicts the 
change of methadone blood concentrations during the last 
24 h upon repeated oral methadone exposure as described 
in the study of Foster et al. (2000) and Liu et al. (2007). 
Table 4 further shows the detailed comparison between the 
model prediction and the in vivo kinetic data using steady-
state blood Cmax and AUC values on the last day of exposure 
as model outcomes. For methadone, the predicted kinetic 
values are in accordance with reported values expressing 
a 0.78- to 1.35-fold difference in Cmax values and 0.76- to 
0.97-fold difference in AUC values (Table 4). 
Table 3  Kinetic constants 
for formation of EDDP from 
methadone obtained from 
in vitro incubations with human 
liver and intestinal microsomes
n.d. not determined, since EDDP and EMDP were unable to be quantified (see text for details)
a Vmax/Km × 1000
b Formation rate at 1000 µM and 1500 µM
–Unable to calculate
Organ Substrate Metabolite Vmax ± SD (nmol/
min/mg microsomal 
protein)
Km ± SD (µM) Catalytic efficiency (µl/
min/mg microsomal 
protein)a
Liver Methadone EDDP 0.82 ± 0.026 275 ± 26.78 2.97
EMDP n.d n.d –
EDDP EMDP n.d n.d –
Intestine Methadone EDDP 0.058, 0.057 b n.d –
EMDP n.d n.d –
Table 4  Summary of in vivo kinetic studies and evaluation of the PBK model predictions for methadone steady-state blood Cmax and AUC val-
ues based on the data derived from in vivo kinetic studies
n.r. not reported, - unable to calculate
a Free base form of methadone
b Blood data were obtained by multiplying reported plasma data by the BPr value
c In vivo Cmax and AUC is the sum of data of enantiomers
d The body weight of subjects was set equal to the value used in the PBK model since body weight of study subjects was not reported
Mean body 
weight (kg)
Mean methadone 
dose (mg/day)a
In vivo 
Cmax (ng/
ml) b
In vivo AUC 
(ng · h/ml) b
Predicted 
Cmax (ng/
ml)
Predicted 
AUC (ng · h/
ml)
Ratio 
predicted
Cmax/
in vivo 
 Cmax
Ratio predicted 
AUC/in vivo 
AUC 
References
74 70 346.2 5097 320.5 4967 0.93 0.97 Foster et al. (2000)c
90 100 453.6 7889 385.2 5969 0.85 0.76 Liu et al. (2007)c
70d 61 216.0 n.r 293.1 4542 1.35 – Diong et al. (2014)
64.7 57.5 383.6 5978 296.4 4591 0.78 0.77 De Vos et al. (1995)
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Sensitivity analysis
Figure 7 shows the most influential model parameters for 
the prediction of steady-state Cmax in the heart venous 
blood upon exposure to oral repeated methadone doses 
of 20 and 200 mg. The results indicate that the normal-
ized sensitivity coefficients of all PBK model parameters 
were not dose dependent until at least 200 mg/day and 
that the predicted steady-state Cmax in the heart venous 
blood is most sensitive to the oral fraction absorbed and 
the body weight with normalized SC values above 0.8. 
The parameters related to liver metabolism (volume of 
liver, liver microsomal protein yield, unscaled maximum 
rate of methadone metabolism) also substantially influ-
ence the model outcome with normalized SC values of 
0.6. The absorption rate constant and the partition coef-
ficient rapidly perfused tissue to blood of methadone are 
less influential with normalized SC value of 0.25 and 0.1, 
respectively.
Translation of in vitro concentration–response 
data into in vivo dose–response data using PBK 
modeling‑based reverse dosimetry
Although EDDP induced concentration-dependent prolon-
gation of FPDc in the in vitro assay, the free blood Cmax of 
EDDP, after an oral dose of 57.5 mg/day, was estimated to 
be 0.05 µM based on EDDP data reported in De Vos et al. 
(1995). Using the current PBK model, the free blood Cmax 
of EDDP was predicted to be 0.17 µM at a relatively high 
dose level of methadone of 200 mg/day. Both the reported 
and predicted free blood Cmax of EDDP are substantially 
lower than unbound concentrations causing cardiotoxicity 
in the hiPSC-CM MEA assay (unbound  BMC20 = 2.07 µM) 
(Fig. 4). To reach the unbound  BMC20 value of 2.07 µM, a 
methadone dose level of 2600 mg/day was estimated to be 
required, which is 22-fold higher than the highest clinical 
relevant dose of 120 mg/day (Chou et al. 2014). Therefore, 
the cardiotoxicity of EDDP was not considered to play a 
role in methadone-induced cardiotoxicity and, thus, also not 
considered for the reverse dosimetry.
Upon correction for protein binding performed using 
the values for fu,m and fu,p described above, the in vitro 
concentration–response curve of methadone obtained in 
the hiPSC-CM as detected by the MEA was translated to 
in vivo dose–response curves for human cardiotoxicity using 
the developed PBK model. As mentioned in the “unbound 
Fig. 6  Blood concentration–time curves of methadone in human predicted with the PBK model (lines) and published in vivo data (dots) after a 
repeated oral dose of 70 mg/day for 60 days a (Foster et al. 2000) and 100 mg/day for 30 days b (Liu et al. 2007)
Fig. 7  Normalized SCs of PBK model parameters for the prediction 
of steady-state Cmax of methadone in the heart venous blood upon 
oral repeated doses of 20 mg/day (white bars) and 200 mg/day (black 
bars). Model parameters with normalized SC with an absolute value 
higher than 0.1 (dotted lines) are shown. BW body weight, VLc frac-
tion of liver, PRmet partition coefficient rapidly perfused tissue:blood 
of methadone, ka absorption rate constant, Fa oral fraction absorbed, 
MPL liver microsomal protein yield, Vmaxc unscaled maximum rate 
of methadone metabolism in liver, Km Michaelis–Menten constant 
for methadone metabolism in liver
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fraction for methadone” section, fu.m of 0.79 was used to cor-
rect for protein binding of methadone in the in vitro medium; 
while for the in vivo situation, four different fu,p values were 
used including the experimental fu,p value obtained from 
pooled human plasma, an in silico-derived fu,p value and 
two extreme fu,p values obtained from the literature (Eap 
et al. 1990; Foster et al. 2000; Moody et al. 2008; Olsen 
1973; Romach et al. 1981; Wilkins et al. 1997). This resulted 
in four predicted in vivo dose–response curves for metha-
done-induced cardiotoxicity, one for each of the fu,p values 
(Fig. 8). These predicted dose–response curves were subse-
quently compared to available in vivo human data.
Evaluation of the PBK modeling‑based reverse 
dosimetry approach and BMD analysis of predicted 
dose–response data
To evaluate the performance of the PBK modeling-based 
reverse dosimetry approach, the dose–response data for 
QTc prolongation obtained from case reports, case series, 
cross-sectional, retrospective and prospective studies were 
compared with the predicted dose–response curves for QTc 
prolongation taking different fu,p values into account. This 
comparison, presented in Fig. 8, reveals that the predicted 
in vivo dose–response curves for QTc prolongation were 
comparable with reported in vivo data. The prediction of 
QTc prolongation with the fu,p value of 0.15 obtained from 
Simcyp is best in line with the majority of reported QTc 
prolongation data of individual cases. The QTc prolonga-
tion data reported in population studies, however, were 
more close to the predicted dose–response curve with the 
fu,p value of 0.055 obtained from the RED assay.
To further evaluate the model predictions a BMD analy-
sis was performed.  BMDL10 values were derived and used 
as points of comparison. Figure 9 presents the  BMDL10 
derived from the dose–response curves presented in Fig. 8, 
predicted with the different fu,p values while also present-
ing therapeutic dose levels of methadone. The comparison 
presented in Fig. 9 reveals that the predicted  BMDL10 val-
ues overlap with the therapeutic methadone dose levels. 
The predicted  BMDL10 values for methadone-induced 
cardiotoxicity based on high fu,p values of 0.22 and 0.15 
are 1.7- and 2.4-fold higher, respectively, than the recom-
mended initial dose for opioid-native patients (10 mg/day), 
and the predicted  BMDL10 values based on low fu,p values 
of 0.055 and 0.034 are 2.2- and 3.6-fold higher, respec-
tively, than the recommended initial dose for opioid users 
(30 mg/day) (Chou et al. 2014; BCCSU 2017). This indi-
cated that these therapeutic dose levels are below the dose 
levels predicted to result in 10% change, an effect size that 
can be used as a threshold to evaluate abnormal QTc pro-
longation (Anchersen et al. 2009; Chou et al. 2014; ICH 
2005b; Mujtaba et al. 2013; Treece et al. 2018). The main-
tenance dose of 60–120 mg methadone/day (Chou et al. 
Fig. 8  Predicted dose–response curves for cardiotoxicity of metha-
done obtained using PBK modeling-based reverse dosimetry com-
pared to in  vivo dose–response data derived from literature. The 
curves represent the prediction based on a fu,p of 0.22 (black line), 
0.15 (red line), 0.055 (blue line) and 0.034 (green line). Symbols rep-
resent the data obtained from case reports, case series of individuals 
(orange triangles) (Esses et  al. 2008; Fredheim et  al. 2006; Krantz 
et  al. 2002) and other studies as follows: Bart et  al. (2017) (purple 
circle); Carlquist et  al. (2015) (orange square); Chang et  al. (2012) 
(green circle) Chowdhury et  al. (2015); (dark blue cross); Cruciani 
et al. (2005) (green cross) Eap et al. (2007); (green star); Ehret et al. 
(2006) (dark blue triangle) Fareed et  al. (2013); (dark blue circle) 
Heesch et al. (2015); (dark blue star) Krantz et al. (2005); (orange cir-
cles) Maremmani et al. (2005); (green square); Martell et al. (2005) 
(green triangle) Peles et al. (2007); (orange star); Reddy et al. (2010) 
(orange circles) Roy et al. (2012); (dark blue square). The in vivo data 
are summarized in Table S1 and S2 (color figure online)
Fig. 9  Comparison of BMDL values derived from the predicted 
dose–response curves for human cardiotoxicity of methadone pre-
sented in Fig. 8 (lines) and therapeutic dose levels reported in the lit-
erature (boxes filled with horizontal lines)
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2014; BCCSU 2017) is, however, 0.6- to 7.2-fold higher 
than the predicted  BMDL10 values in all scenarios, point-
ing at a potential cardiotoxic effect in especially individu-
als with relatively lower plasma protein binding (higher 
fu,p). Detailed information on the BMD analysis can be 
found in the supplementary materials 1 Tables S3–S7 and 
the BMD values are summarized in Table S7.
Discussion
The aim of the present study was to investigate whether 
human in vivo cardiotoxicity could be predicted by a novel 
testing strategy combining the in vitro toxicity assay with 
hiPSC-CM in a MEA and PBK modeling-based reverse 
dosimetry. Methadone was used as the model compound 
given that for this drug, both kinetic and clinical human 
data for evaluation of predictions made were available.
The in vitro electrophysical cardiotoxicity was detected 
using hiPSC-CM combined with the MEA technology, 
which can capture the overall effects on multiple ion 
channels on the extracellular field potential. The change 
in FPDc in the in vitro obtained field potential waveforms 
can be considered a surrogate endpoint for the QTc inter-
val in the human ECG (Zwartsen et al. 2019), the param-
eter known to be indicative for methadone-induced car-
diotoxicity (Mujtaba et al. 2013). The results show that 
methadone induced a concentration-dependent prolonga-
tion of FPDc which is in line with the study of Kury-
shev et al. (2010) reporting that methadone prolonged the 
action potential duration using patch clamp recordings in 
human cardiomyocytes. Studies using mammalian cells 
transfected with cardiac ion channels revealed that the 
prolonged effect on FPDc can be ascribed to the inhibi-
tion of the hERG and sodium channels (Eap et al. 2007; 
Kuryshev et al. 2010). The major methadone metabolite 
EDDP appeared to also prolong the FPDc albeit with lower 
potency than methadone. This lower potency of EDDP 
is in line with the fact that EDDP was reported to be a 
weaker hERG channel blocker compared to methadone 
(Eap et al. 2007; Katchman et al. 2002); while, effects 
on other ion channels such as sodium channel may con-
tribute to the observed EDDP-induced FPDc prolongation 
effect (Mishra et al. 2014). Neither FPDc prolongation nor 
arrhythmia-type waveforms were observed upon exposure 
of the hiPSC-CM to EMDP which is in accordance with 
the previous study reporting EMDP to not inhibit hERG 
channels (Eap et al. 2007). Given that the in vivo total 
plasma concentration of EMDP has been reported to be 
less than 0.04 µM after clinical relevant dosing (Alburges 
et al. 1996), it can be concluded that the in vitro effects 
of EMDP in the hiPSC-CM MEA assay, with an in vitro 
 BMC20 for decreasing FPDc of 3.8 µM, would not be 
relevant in in vivo. Thus, the methadone-induced pro-
longation of the FPDs is unlikely to be counteracted by 
EMDP and the cardiotoxicity of EMDP was not further 
taken into account.
The evaluation of the developed PBK model against 
literature data available on steady-state blood Cmax and 
AUC values of methadone (De Vos et al. 1995; Diong 
et al. 2014; Foster et al. 2000; Liu et al. 2007), indicated 
that the model was able to adequately predict the kinetics 
of methadone with differences being less than twofold, 
which is generally accepted as an adequate predictive per-
formance (Badhan et al. 2019; WHO 2010).
It is generally assumed that the unbound concentration is 
responsible for the clinical response of a drug (Smith et al. 
2010). Given that methadone is a lipophilic drug with basic 
properties, the extent of protein binding may play an impor-
tant role in determining the free concentration and influence 
the therapeutic or toxic effects of methadone. Given that 
in vivo experimental data report variation in the fu,p values 
of methadone, the PBK modeling-based reverse dosimetry 
was performed taking into account different values for fu,p. It 
is reported that the fraction of unbound methadone is signifi-
cantly correlated to the plasma concentration of alpha1-acid 
glycoprotein (AAG) (Abramson 1982; Yang et al. 2006), 
which is known to be influenced by physiological and patho-
logic conditions of the subject (Eap et al. 1990). The 1.5- to 
6.5-fold difference in the four  fu,p values used for the PBK 
modeling-based reverse dosimetry are in line with the 2- to 
20-fold variation of the AAG concentration among individu-
als (Taguchi et al. 2013).
The predicted dose–response curves obtained from the 
PBK modeling-based reverse dosimetry, using the respec-
tive fu,p values were in line with in vivo data available from 
case reports, case series, cross-sectional, retrospective and 
prospective studies on methadone induced effects on in vivo 
QTc prolongation available in the literature (Fig. 8). This 
further validates the developed PBK model and provides 
support for the novel in vitro–in silico testing strategy for 
prediction of cardiotoxicity in human.
It is of interest to note that the predictions with high fu,p 
values (0.22 and 0.15) are more in line with data obtained 
from individual case series; while, the data obtained with 
lower fu,p values (0.055 and 0.034) especially match the data 
from population studies. The reasons underlying this obser-
vation remain to be elucidated but may be related to the fact 
that the concentration of AAG increases under the condi-
tions of heroin addiction (Garrido et al. 2000), HIV infec-
tion (Barrail-Tran et al. 2010), and cancer (Huang and Ung 
2013). Given that the subjects in the epidemiological stud-
ies were associated with those physiological and pathologic 
conditions, smaller fu,p values would be expected; while, 
the individual case series were selected using criteria that 
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specifically exclude these potential factors that interfere with 
the concentration of AAG.
To further evaluate the in vitro–in silico predictions for 
human cardiotoxicity of methadone,  BMDL10 values derived 
from predicted dose–response curves were compared to ther-
apeutic doses. The  BMDL10 values appeared to overlap with 
the therapeutic dose levels. Given the fact that a  BMDL10 
value is generally considered a dose level that is comparable 
to a no observed adverse effect level (EFSA 2017), and 10% 
effect is an effect size used as a threshold to evaluate abnor-
mal QTc prolongation (Anchersen et al. 2009; Chou et al. 
2014; ICH 2005b; Mujtaba et al. 2013; Treece et al. 2018), 
doses lower than the predicted  BMDL10 values would be 
expected to be without an effect on QTc prolongation, which 
is in line with the observation that the predicted  BMDL10 
values based on high fu,p values and low fu,p values are two- 
to threefold higher than the recommended initial dose for 
opioid-native patients (10 mg/day) and opioid users (30 mg/
day), respectively (Chou et al. 2014; BCCSU 2017). The 
fact that the  BMDL10 values obtained with the relatively 
higher fu,p values are 2.5- to sevenfold lower than the mainte-
nance dose (60 mg/day), may explain the QTc prolongation 
observed in some methadone maintenance treatment patients 
given these therapeutic maintenance dose levels. This con-
firms the need for particular cautions (intensive ECG moni-
toring and determining arrhythmia risk factor) for patients 
receiving high doses of methadone (> 100 mg) (Florian et al. 
2012; Mujtaba et al. 2013; Treece et al. 2018). Krantz et al. 
(2002) reported that methadone induced Tdp in patients, 
without the presence of other risk factors, prescribed an 
average dose of 400 mg/day, which is consistent with our 
predictions given the fact that this dose is even fourfold 
higher than the  BMDL10 value (109 mg/day) derived from 
the predictions based on the lowest fu,p values. The results of 
our study indicate that especially subjects with lower levels 
of plasma protein binding (higher fu,p) of methadone may be 
a group at extra risk.
The results of the present study indicate that fu,p may be 
a key parameter causing interindividual differences in the 
cardiotoxicity of methadone. The exact magnitude of the 
effect of changes in protein binding on toxicity, however, is 
not always straightforward since this is an interplay between 
the available fraction at the site of action, metabolism and 
excretion and may, i.e., require detailed information on the 
fate of a compound within cells/the human body which is 
often not available. Moreover, the variability in other factors 
that influence the concentration in the heart venous blood 
may also cause variation in cardiotoxic effects in individuals. 
Based on the sensitivity analysis, the Cmax in heart venous 
blood is also influenced by metabolism-related parameters. 
A major enzyme involved in the metabolism of methadone 
to EDDP is CYP2B6, a cytochrome P450 that shows large 
interindividual variability due to genetic polymorphism 
(Kharasch 2017). It would be of interest to integrate also 
this variability in the PBK model-based reverse dosimetry 
approach and predict its influence on the in vivo effects of 
methadone. This is a topic beyond the aim of the present 
study, that is currently under investigation. In addition, given 
that methadone is the racemic mixture of R- and S-metha-
done and the latter enantiomer is mainly responsible for the 
cardiotoxic effects (Ansermot et al. 2010; Eap et al. 2007; 
Lin et al. 2009), it would also be of interest to predict metha-
done induced cardiotoxicity distinguishing between the R- 
and S-enantiomers.
In the present study, we demonstrated the integration of 
the hiPSC-CM MEA data and PBK modeling-based reverse 
dosimetry to assess the in vivo cardiotoxicity of methadone 
in human. This in vitro–in silico approach enabled the 
translation of the in vitro concentration–response data on 
cardiotoxicity to predicted in vivo dose–response data for 
methadone-induced QTc prolongation in human. Compari-
son of model predictions to in vivo data revealed that the 
novel testing strategy provided adequate predictions for both 
in vivo kinetics and cardiotoxicity of methadone, also pin-
pointing to an important role for binding to plasma proteins 
in determining potential interindividual differences in sen-
sitivity towards the cardiotoxic effects of methadone. The 
present study provides a proof-of-principle of using PBK 
modeling-based reverse dosimetry for QIVIVE to predict 
cardiotoxicity in human, providing a novel testing strategy 
for cardiac safety.
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